Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 50

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
umulated deficit(801,215)(795,761)Accumulated other comprehensive loss(30,006)(33,763)Total shareholders' equity396,564 360,716 Total liabilities and shareholders' equity$1,102,500 $1,009,506 

The accompanying notes form an integral part of these condensed consolidated financial statements.

2

Table of Contents

 Immunocore Holdings plc

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited) (In thousands, except share and per share data)

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenue:Revenue from sale of therapies, net$103,693 $80,248 $295,538 $225,937 Collaboration revenue— — — 213 Total revenue103,693 80,248 295,538 226,150 Cost and operating expenses:Cost of revenue from sale of therapies(513)(448)(2,384)(2,401)Research and development expense(70,572)(52,770)(196,048)(161,301)Selling, general and administrative expense(39,779)(35,532)(122,768)(113,457)Loss from operations(7,171)(8,502)(25,662)(51,009)Other income (expense):Interest income4,123 5,960 12,570 20,445 Interest expense(3,043)(4,290)(9,113)(11,806)Foreign currency gain1,333 3,963 3,675 1,049 Other income, net5,062 8,962 15,224 13,205 Net income (loss) before income taxes304 6,093 (3,306)(28,116)Income tax (expense) benefit(481)2,643 (2,148)800 Net (loss) income$(177)$8,736 $(5,454)$(27,316)Other comprehensive (loss) income:Exchange differences on translation of foreign operations(3,392)3,247 3,757 5,088 Total comprehensive (loss) income$(3,569)$11,983 $(1,697)$(22,228)Basic net (loss) income per share$(0.00)$0.17 $(0.11)$(0.55)